Marc Wade  Rosenbaum net worth and biography

Marc Rosenbaum Biography and Net Worth

Marc Rosenbaum is the CAO of iRhythm Technologies. They are 53 years old.

What is Marc Wade Rosenbaum's net worth?

The estimated net worth of Marc Wade Rosenbaum is at least $1.49 million as of February 24th, 2026. Rosenbaum owns 10,601 shares of iRhythm Technologies stock worth more than $1,486,048 as of February 26th. This net worth approximation does not reflect any other investments that Rosenbaum may own. Learn More about Marc Wade Rosenbaum's net worth.

How old is Marc Wade Rosenbaum?

Rosenbaum is currently 52 years old. There are 7 older executives and no younger executives at iRhythm Technologies. Learn More on Marc Wade Rosenbaum's age.

How do I contact Marc Wade Rosenbaum?

The corporate mailing address for Rosenbaum and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Marc Wade Rosenbaum's contact information.

Has Marc Wade Rosenbaum been buying or selling shares of iRhythm Technologies?

During the past quarter, Marc Wade Rosenbaum has sold $39,454.80 in shares of iRhythm Technologies stock. Most recently, Marc Wade Rosenbaum sold 280 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $140.91, for a transaction totalling $39,454.80. Following the completion of the sale, the chief accounting officer now directly owns 10,601 shares of the company's stock, valued at $1,493,786.91. Learn More on Marc Wade Rosenbaum's trading history.

Who are iRhythm Technologies' active insiders?

iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Marc Rosenbaum (CAO), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Abhijit Talwalkar (https://www.linkedin.com/in/dasdan), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.

Are insiders buying or selling shares of iRhythm Technologies?

In the last year, insiders at the sold shares 18 times. They sold a total of 83,566 shares worth more than $14,082,662.53. The most recent insider tranaction occured on February, 24th when CAO Marc Wade Rosenbaum sold 280 shares worth more than $39,454.80. Insiders at iRhythm Technologies own 1.1% of the company. Learn More about insider trades at iRhythm Technologies.

Information on this page was last updated on 2/24/2026.

Marc Wade Rosenbaum Insider Trading History at iRhythm Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2026Sell280$140.91$39,454.8010,601View SEC Filing Icon  
8/11/2025Sell226$158.93$35,918.1810,879View SEC Filing Icon  
See Full Table

Marc Wade Rosenbaum Buying and Selling Activity at iRhythm Technologies

This chart shows Marc Wade Rosenbaum's buying and selling at iRhythm Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iRhythm Technologies Company Overview

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $140.18
Low: $136.01
High: $140.67

50 Day Range

MA: $162.29
Low: $135.90
High: $189.25

2 Week Range

Now: $140.18
Low: $92.52
High: $212.00

Volume

390,033 shs

Average Volume

725,398 shs

Market Capitalization

$4.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06